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Histomorphology, immunohistochemistry (IHC), and genetics are essential tools for the
evaluation and classiﬁcation of lymphoid malignancies. Advances in diagnostic techniques
include the development of immunohistochemical assays that can serve as surrogates for
genetic tests. We review the performance of a select subset of assays that detect the aberrant
expression of onco-proteins secondary to chromosomal translocations (MYC; BCL2), somatic
mutations (BRAF V600E; NOTCH1), and gene copy number gains (CD274 (encoding PD-L1);
PDCD1LG2 (encoding PD-L2)) in ﬁxed tissue biopsy sections. We discuss the limitations of
IHC, but also its primary advantage over genetics; speciﬁcally, its ability to assess the ﬁnal,
common phenotypic consequences of a multitude of genetic and non-genetic events that
inﬂuence protein expression. The information provided by IHC and genetic testing are thus
intimately related; surgical pathologists will increasingly need to interpret and integrate the
results of both to provide a comprehensive assessment of tumor biology and guide therapy.
& 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Our understanding of the classiﬁcation and underlying
pathogenesis of lymphomas has improved tremendously in
the past few decades, as recurrent genetic alterations have
been described in a large number of lymphoproliferative
disorders. In some cases, these alterations are known to be
oncogenic drivers, while others have unclear functions. The
cumulative effect is to promote tumorigenesis through the
aberrant expression and function of proteins that affect
critical intracellular signaling pathways, growth factors or
their receptors, and the cellular microenvironment. Genetic
testing is increasingly being used in conjunction with immu-
nohistochemistry (IHC) to facilitate tumor classiﬁcation inElsevier Inc. This is an o
nd/4.0/).
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Rodig).routine diagnostics. Common tests include tumor cell karyo-
type to establish the identity, number, and structural rear-
rangements of chromosomes by morphology, ﬂuorescence
in situ hybridization (FISH) of labeled DNA probes to tumor
cell nuclei to screen for speciﬁc chromosomal translocations
or genetic copy gains or loss, and next-generation sequencing
of nucleic acids from unfractionated tumors to survey for
hundreds or thousands of somatic mutations. Genetic testing
is appealing because the results are easily quantiﬁable and
come from an analyte (DNA) that is extremely stable.
IHC uses antibodies to detect the expression of speciﬁc
proteins in tissue sections and, in contrast to genetic testing,
the analytes are labile. The results of IHC can be seriously
affected by pre-analytical variables, such as the chemicalspen access article under the CC BY-NC-ND license
pplication submitted on the use of PD-L1 immunohistochemical
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the protocols used for tissue processing. In addition, the
results of IHC are reliant upon the performance of speciﬁc
antibodies on speciﬁc tissue types. Given these factors,
optimal staining protocols must be determined empirically
for every individual test. In addition, substantial experience
in recognizing the staining patterns resulting from any of the
hundreds of tests available to diagnostic pathologists is
critical for accurate interpretations.
Despite these limitations, IHC remains an essential tool in
diagnostic laboratories for several reasons. First, pathology
laboratories have had decades of experience with IHC, which
can be performed routinely, economically, and quickly. Sec-
ond, IHC captures essential phenotypic information that
cannot be determined by genetic analysis alone, such as a
tumor ’s cell of origin. Third, IHC preserves the histomorpho-
logical features of a tumor, which facilitates the interpreta-
tion of the results. Fourth, IHC can detect disrupted protein
expression due to a variety of genetic, epigenetic, transla-
tional, post-translational, and microenvironmental aberra-
tions rather than focusing on speciﬁc genetic changes.
This article will focus on a few examples of how recent
scientiﬁc discoveries have improved our understanding of
IHC ﬁndings in correlation with the underlying genetic
lesions in various lymphoid neoplasms, and hence our
abilities to utilize IHC results in detecting or screening for
these lesions.
MYC
The MYC (c-MYC) gene on chromosome 8 at band q24 codes
for a multifunctional nuclear protein that acts as a transcrip-
tional activator or repressor, which plays a critical role in cell
growth, cell cycle progression, apoptosis, angiogenesis, and
cellular transformation.1 A balanced translocation involving
the MYC gene is the hallmark feature of Burkitt lymphoma
(BL), the ﬁrst lymphoma in which a recurrent chromosomal
abnormality was described.2,3 Most commonly, the trans-
location juxtaposes MYC with the immunoglobulin heavy
chain gene (IGH) enhancer on chromosome 14q32 (approx-
imately 80% of cases) or, less frequently, the immunoglobulin
kappa gene (IGK) on chromosome 2p12 or the lambda light
chain gene (IGL) on chromosome 22q11.4 MYC translocations
involving non-immunoglobulin genes, such as PAX5 (chro-
mosome 9p13) and BCL6 (chromosome 3q27), have also been
described.5–7 Each of these translocations leads to constitu-
tive expression of the MYC transcript and protein in the
malignant cells.
Traditionally, BL is diagnosed through recognition of ster-
eotypical histomorphological features, coexpression of anti-
gens associated with mature, germinal center B-cells, and
genetic studies demonstrating a chromosomal rearrange-
ment involving 8q24. The detection of the MYC oncoprotein
in tumor cells by IHC would seem an obvious way to conﬁrm
a diagnosis of BL in the absence of genetic testing. Yet, early
studies on MYC IHC yielded conﬂicting results, possibly due
to the lack of antibodies amenable to detecting the protein in
ﬁxed tissues.8,9 More recently, however, it was found that a
novel monoclonal rabbit anti-human MYC antibody (Y69
clone, Epitomics Inc.) was useful for detecting MYC informalin-ﬁxed, parafﬁn-embedded (FFPE) tissue sections.10
In an initial study of MYC IHC using BL cases, most (15/17
cases) with conﬁrmed MYC translocations, it was found that
the tumor cells comprising the majority of the cases (88%)
demonstrated intense nuclear staining for the oncoprotein,
while the remaining cases showed equal intensity of nuclear
and cytoplasmic staining. In contrast, almost all cases (18/19
cases; 95%) of diffuse large B-cell lymphoma (DLBCL) without
MYC rearrangement (MYC–DLBCL) lacked nuclear staining of
the tumor cells for MYC.10 This initial study also included
a small number of DLBCL with MYC rearrangement
(MYCþDLBCL) and B-cell lymphoma, unclassiﬁable, with
features intermediate between DLBCL and BL (BCL-U). MYC
IHC showed intense nuclear staining for the oncoprotein in
these cases as well. Overall, nuclear staining for MYC was
found to be 96% sensitive and 90% speciﬁc forMYC rearrange-
ment, with high positive and negative predictive values (0.92
and 0.95, respectively) and a high inter-observer concordance
in classifying the MYC staining pattern between two pathol-
ogists (kappa statistic ¼ 0.90). The results suggested that IHC
effectively captures the dysregulated expression of the MYC
oncoprotein in BL, the prototypical tumor harboring a MYC
translocation.
MYC translocations occur in additional lymphoid malig-
nancies, including plasmablastic lymphoma, transformed
follicular lymphoma, blastoid mantle cell lymphoma, and de
novo DLBCL, albeit at much lower frequencies than observed
for BL.11–13 Approximately 10–15% of patients with de novo
DLBCL are MYCþ, and a number of studies have demon-
strated that these patients have inferior 5-year progression-
free survival and overall survival rates, higher rate of central
nervous system relapse, as well as poor responses to CHOP or
R-CHOP chemotherapy compared to patients with de novo
MYC– DLBCL when treated with standard immuno-
chemotherapy.14–17
MYC IHC has been tested on genetically annotated DLBCLs
in several studies. It was found that high nuclear MYC
staining by IHC (450% of tumor cells) was detected not only
in all MYCþ DLBCLs, but also in a subset of MYC– DLBCLs.18
Both MYCþ and MYC– DLBCLs with high MYC protein were
found to exhibit high MYC transcript and MYC target gene
expression by gene set enrichment analysis (GSEA). More-
over, the transcriptional signature of DLBCLs with high MYC
protein expression resembled that of the so-called molecular
Burkitt lymphoma (mBL) reported previously.14,19 Finally,
DLBCL cases with high MYC protein expression were shown
to have poorer overall survival after R-CHOP chemotherapy
compared to DLBCLs with low MYC protein expression.18 The
mechanisms responsible for MYC dysregulation in MYC–
DLBCL with high MYC protein are under active investigation
but are likely multi-factorial and include MYC copy number
gain, dysregulated micro-RNAs that govern MYC transcript
abundance, and mutations in MYC itself.1,18,20 Fig. 1 shows
examples of two cases of DLBCL with high nuclear MYC
staining by IHC. One showed MYC gene rearrangement as
demonstrated by FISH study, while the other one did not
show MYC gene rearrangement.
Several subsequent studies have validated the negative
prognostic signiﬁcance of MYC overexpression in patients
with DLBCL treated with R-CHOP, especially in the context of
Fig. 1 – MYC IHC in two diffuse large B-cell lymphomas (DLBCL). (A) DLBCL case with high MYC protein expression and
demonstrated MYC gene rearrangement by FISH using break-apart probes (inset). (B) DLBCL case with high MYC protein
expression, but no MYC gene rearrangement detected by FISH using break-apart probes (inset).
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more sensitive than conventional karyotyping and FISH in
detecting MYC-driven DLBCLs, as up to 50% of DLBCLs with
high MYC protein and high MYC biological activity lack aMYC
translocation. However, the challenge for pathologists incor-
porating MYC IHC into routine practice remains the employ-
ment of rigorously standardized staining and scoring
protocols to ensure reproducible results on a daily basis.
BCL2
BCL2 (B-cell leukemia–lymphoma-2), located on chromosome
region 18q21, codes for a protein that is expressed normally
by resting T and B cells, but not by normal germinal center
cells or cortical thymocytes, and regulates cell death by
functioning as an important anti-apoptotic protein.26–27 It
was originally cloned from follicular lymphomas cell lines
with t(14;18)(q32;q21), which juxtaposes the immunoglobulin
heavy chain gene IGH promoter with BCL2, and is now known
to be characteristic of up to 90% of follicular lymphomas (FLs).
BCL2 translocations have also been observed in a subset of
DLBCLs,28–32 but they were not observed in Hodgkin and other
types of non-Hodgkin lymphomas.31 This translocation is
also absent in many grade 3B FLs, which are likely more
closely related to DLBCL.33 The translocation results in a
hybrid transcript consisting of the 50 half of the BCL2 mRNA
fused to an IGH mRNA, which continues to encode a normal
but overexpressed BCL2 protein, as the breakpoint is located
outside the BCL2 coding region.34 Overexpression of BCL2
confers survival advantage by preventing apoptosis, as dem-
onstrated by an in vitro experiment on growth factor-
deprived hematopoietic cell lines.35
Although t(14;18)(q32;q21) is a characteristic of FL, in
practice, the diagnosis of FL is usually made by a combination
of cellular morphology (typically a combination of centro-
cytes and centroblasts), architectural pattern (typically at
least partially follicular), IHC positivity for antigens associ-
ated with mature, germinal center B cells, and the detectionof aberrant BCL2 protein expression by the malignant cells.36
There are several caveats to consider applying BCL2 IHC as a
surrogate for genetic testing. First, BCL2 expression is more
frequent among grades 1–2 FL cases (85–97%) compared to
grade 3 cases (50–75%), consistent with the distribution of
t(14;18) in these tumors.37,38 Second, BCL2 is also expressed
by the malignant cells of various other low-grade B-cell
lymphomas, such as mantle cell lymphoma and marginal
zone lymphoma, although the characteristic t(14;18) is
absent.36 Third, and most importantly, up to 10% of FLs are
negative for BCL2 by IHC using the conventional monoclonal
antibody raised against residues 41–54 of the BCL2 protein.39
In a study by Schraders et al., grades 1, 2, and 3A FLs that
were negative or showed heterogenous staining for BCL2 IHC
with the standard antibody were stained with alternative
antibodies raised against residues 1–201 as well as against the
whole BCL2 protein. Five of these 18 cases were positive for
BCL2 using the alternative antibodies, and these cases
showed t(14;18) by FISH analysis. Of the remaining FL cases,
one case had t(14;18) but was negative for BCL2 using all the
antibodies tested. Twelve cases lacked t(14;18) and were
negative for BCL2 by IHC using the standard and alternative
antibodies. PCR and sequencing analysis on the cases show-
ing BCL2 positivity with the alternative antibodies, which all
harbor t(14;18), demonstrated somatic BCL2 mutations in a
subset of cases, resulting in amino acid replacements within
the epitope recognized by the conventional antibody.39 To
provide further proof of the usefulness of alternative anti-
bodies raised against different residues of the BCL2 protein, in
a study by Masir et al., only about 50% of the 33 cases of
t(14;18)-positive FL cases were strongly positive for BCL2 by
IHC using a widely used monoclonal antibody BCL2/124
targeting residues 41–54. 20% of the cases were negative for
BCL2 with the conventional antibody but were positive using
an alternative antibody (clone E17 targeting residues 61–76).27
Sequencing of the genomic region encoding the epitope
recognized by the two different BCL2 antibodies showed that
some cases harbored BCL2 mutations resulting in amino acid
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tional BCL2/124 antibody, just like in the study by Schrader
et al. The remaining 30% of the cases showed heterogeneous
positivity for BCL2, using both the BCL2/124 and the clone E17
antibodies.27 In summary, BCL2 IHC is commonly used as a
surrogate for genetic testing in cases of suspected FL. IHC is
not infallible, as BCL2 negativity can be observed in FL cases
with t(14;18) due to mutations within the epitope recognized
by the anti-BCL2 antibody. The use of multiple antibodies
targeting different epitopes can largely overcome this prob-
lem. Fig. 2 shows an example of follicular lymphoma involv-
ing the bone marrow, wherein the tumor cells are negative by
IHC using a conventional BCL2 antibody clone 124 and
positive using an alternative BCL2 antibody clone E17.
In aggressive B-cell lymphomas, BCL2 translocations have
been primarily evaluated in the context of co-existent MYC
translocations, where the presence of both identiﬁes a subset
of tumors with dismal prognosis. A Canadian study on B-cell
non-Hodgkin lymphomas with concurrent translocations
involving BCL2 and MYC, including cases of de novo DLBCL;
DLBCL transformed from FL or chronic lymphocytic leukemia;
and B-cell lymphoma unclassiﬁable (BCL-U) showed that
close to 60% died within 6 months of diagnosis, and only
11% remained in remission in 5 years.40 The median survival
remained short despite the addition of Rituximab to the
CHOP therapy, or the use of high-dose chemotherapy with
stem cell transplantation.40 The inferior prognosis of so-
called “genetic double-hit lymphomas” (MYC and BCL2 trans-
locations) has been conﬁrmed in additional series.41
BCL2 is expressed in a greater percentage of aggressive B-
cell lymphomas than those that harbor the t(14;18), and its
expression provides prognostic information. An early study
found that high BCL2 protein expression had an adverse
effect on overall survival within the activated B-cell (ABC)
group of DLBCL, but not within the germinal center B-cell-like
(GCB) group, although the study did not take into consider-
ation the presence of MYC gene translocation or MYC protein
expression in these cases, factors that have been associated
with poor prognosis.42 Subsequent studies have focused on
the synergistic effects of BCL2 and MYC overexpression inFig. 2 – BCL2 IHC in a follicular lymphoma involving the bone ma
is negative in the tumor cells. (B) BCL2 IHC using the alternativepredicting patient outcomes in high-grade B-cell lymphomas.
A study by Johnson et al. found that among a cohort of DLBCL
patients treated with R-CHOP, poor overall and progression-
free survival were only seen in the group with both BCL2 and
MYC positivity by IHC (deﬁned as Z50% and Z40% tumor
cells showing positivity, respectively). The negative prognos-
tic impact was signiﬁcant for the MYC/BCL2 positive cases by
IHC, regardless of the BCL2 translocation status, and persisted
even after adjusting for the International Prognostic Index
(IPI) score and cell-of-origin (COO) gene signatures (ABC vs.
GCB groups).22 Similarly, a study by Hu et al.24 found that
high BCL2/MYC coexpression, as detected by IHC (deﬁned as
Z70% and Z40% tumor cells showing positivity, respec-
tively), was associated with signiﬁcantly worse overall and
progression-free survival rates, after adjusting for the IPI
scores and other clinico-pathological parameters. Meanwhile,
neither MYC nor BCL2 expression alone signiﬁcantly
impacted survival rates. BCL2/MYC-positive cases correlated
signiﬁcantly with DLBCL of ABC type, a group associated with
inferior outcome, as determined by a combination of GEP and
IHC data. After excluding all BCL2/MYC-positive cases within
the DLBCL ABC group, the remaining cases have similar
prognoses to the cases of GCB type.24 Finally, a study by
Green et al.21 also found that high expression of both MYC
and BCL2 in DLBCL, as detected by IHC using the same cutoff
as the study by Hu et al., was signiﬁcantly associated with
lower complete treatment response rate and shorter survival,
independent of the IPI score. Again, neither MYC nor BCL2
gene rearrangement alone signiﬁcantly impacted prognosis.
The ﬁndings in these and other similar studies led to the
proposal of various scoring systems that utilized the expres-
sion of MYC, BCL2, and BCL6, as detected by IHC, in stratifying
DLBCL patients into prognostic subgroups. The study by
Green et al.21 proposed a double-hit score that ranged from
0 to 2, using IHC results for MYC and BCL2. On the other hand,
a study by Horn et al.23 found that a scoring system with a
total score of 0–3, by assigning a risk score of 1 to each of the
adverse features (high MYC, high BCL2, and low BCL6 expres-
sion), can predict overall survival and event-free survival
independent of the IPI score. In summary, genetic studiesrrow. (A) BCL2 IHC using the conventional antibody clone 124
antibody clone E17 is positive in the tumor cells.
Fig. 3 – BRAF V600E-speciﬁc IHC in hairy cell leukemia
involving the bone marrow. BRAF V600E-speciﬁc IHC shows
diffuse cytoplasmic positivity in the tumor cells. The
presence of the mutation was conﬁrmed by pyrosequencing
of tumor DNA isolated from parafﬁn-embedded sections.
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translocations, so-called “double-hit lymphomas,” which is a
group associated with poor treatment response and survival.
However, detection of protein overexpression of MYC and
BCL2 by IHC identiﬁes a larger group of DLBCL cases, so-called
“double-hit score lymphomas” that also have a poor prog-
nosis, many of which are not driven by MYC or BCL2 gene
translocations and are therefore not captured through rou-
tine genetic studies.
BRAF V600E
BRAF, also known as v-Raf murine sarcoma viral oncogene
homolog B, codes for a serine threonine kinase that is part of
the RAF/MEK/ERK cascade, also known as the ERK/MAP
kinase pathway. It is a signaling pathway that mediates
cellular responses to growth signals, cell differentiation, and
survival.43–45 The most common somatic mutation in BRAF
among human tumors leads to the substitution of glutamic
acid for valine at codon 600 (V600E), which has often been
found in melanomas46,47 and papillary thyroid cancers.48,49
The amino acid substitution results in the activation of
BRAF,46,49 which in turn, leads to abnormal activation of the
ERK/MAP kinase pathway to promote tumor growth.46–48
BRAF inhibitors have shown efﬁcacy in the treatment of solid
tumors with the BRAF V600E mutation.50,51
During whole-exome sequencing in search of mutations
associated with hairy cell leukemia (HCL), the BRAF V600E
mutation was found in the peripheral blood samples or
marrow biopsy of all 48 cases studied.52 This mutation was
not found in the matched non-neoplastic cells from the same
patients or patients with other types of B-cell lymphomas/
leukemias that can be difﬁcult to distinguish from HCL,
including splenic marginal zone lymphoma (SMZL) and hairy
cell leukemia-variant (HCL-v). Furthermore, MEK and ERK,
downstream kinase targets of BRAF, were shown to be
phosphorylated (activated) in the HCL samples, and the
degree of phosphorylation decreased with a BRAF inhibitor.52
Thus, exome sequencing revealed a molecular hallmark for
HCL and suggested a novel therapy for this disease.
Given that BRAF V600E is a common mutation observed in
several neoplasms, a novel monoclonal antibody (clone VE1)
recognizing the mutated protein was generated, validated for
IHC53 and subsequently applied to HCL.54 BRAF V600E-speciﬁc
IHC demonstrated cytoplasmic positivity in all 32 HCL bone
marrows, which were mostly conﬁrmed to have the speciﬁc
mutation by direct DNA sequencing, except two cases with low
tumor burden (o15%), thought to be below the detection
threshold of heterozygous mutation by Sanger sequencing.
The mutation-speciﬁc IHC was also positive in one case of
CLL/SLL with conﬁrmed BRAF V600E mutation, but negative in
a variety of other B-cell neoplasms.54 Thus the BRAF V600E-
speciﬁc IHC is useful for establishing a diagnosis of HCL and to
exclude the diagnoses of SMZL and HCL-v. Fig. 3 shows a case
of hairy cell leukemia involving the bone marrow with pos-
itivity for BRAF V600E-speciﬁc IHC, which was conﬁrmed to
harbor the mutation by pyrosequencing.
Besides HCL, the BRAF V600E mutation is also found in close
to 60% of Langerhans cell histiocytosis (LCH), a rare disease with
no previously reported recurrent genomic abnormalities.55 Earlystudies suggest that mutation-speciﬁc IHC will be useful for the
diagnostic evaluation of LCH as well.56,57
The extreme speciﬁcity of mutation-speciﬁc IHC is also its
limitation. A more recent study described a rare subtype of
HCL lacking a mutation in BRAF but with an activating
mutation in MAP2K1, which codes for MEK1, a direct effector
of BRAF.58 These HCLs express the IGHV4-34 immunoglobulin
variable heavy chain, and as a group, have higher disease
burden, worse response to treatment, and shorter survival
compared to typical HCL.58,59 These cases would not be
expected to be captured by BRAF V600E-speciﬁc IHC. How-
ever, one can speculate that IHC tests targeting downstream
signaling molecules in the ERK/MAP kinase pathway, such as
phospho-ERK (pERK), may capture lymphomas with dysregu-
lated ERK/MAPK signaling in general.60,61
As a conclusion, the BRAF V600E mutation is the most
common mutation detected in HCL, and this speciﬁc mutation
can be detected by IHC. In contrary to IHC for MYC and BCL2,
both of which aim to detect the ﬁnal result of protein over-
expression by a variety of mechanisms, IHC for BRAF V600E
aims to detect an altered protein produced by a speciﬁc genetic
mutation. In this case, the advantages of IHC over genetic
studies are the former method ’s faster turnaround time, lower
cost, and possibly higher sensitivity, when compared to PCR-
based mutation detection from FFPE tissue. Usage of pERK IHC
could potentially detect HCL cases with a broader range of
genetic alterations, as some of these cases can have mutations
other than BRAF V600E that cause dysregulation of the ERK/MAP
kinase pathway. However, additional studies will be needed to
validate its sensitivity and speciﬁcity in HCL and HCL-v cases.NOTCH1
NOTCH1, located on chromosome 9, encodes a heterodimeric
transmembrane protein that acts as a ligand-activated tran-
scription factor. Notch1 plays a key role in determining cell
fate, including the differentiation of lymphoid precursors into
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proteolytic cleavages eventually lead to the cleavage of the
Notch receptor’s transmembrane domain, liberating the
Notch intracellular domain (NICD), allowing its translocation
to the nucleus with transcriptional activation of multiple
target genes, including MYC and NF-κB.64–67
NOTCH1 can function as either a tumor suppressor gene, or
as an oncogene, depending on the cellular context.68 The
chromosomal translocation t(7;9)(q34;q34.3) was recognized
in rare cases of T-cell acute lymphoblastic leukemia/lym-
phoma (T-ALL) and, upon cloning, was found to fuse the
intracellular domain of NOTCH1 to the beta T-cell receptor
locus.69 The subsequent introduction of active NOTCH1 alleles
into mice resulted in the development of T-cell neoplasms,
consistent with an oncogenic role for the truncated protein.70
However, chromosomal translocation is a rare mechanism
of pathogenesis in T-ALL.62,69 Weng et al.71 described up to
50–60% of T-ALL cases contained activating NOTCH1 muta-
tions. These mutations can affect the heterodimerization
(HD) domain (most common), the proline glutamate serine
threonine (PEST) domain, or both.62,71–73 Mutations in the HD
domain enhance cleavage of Notch1 to NICD, in some cases
in a ligand-independent manner, while mutations in the
PEST domain reduce the degradation of NICD.64,71 The ﬁnal
common result is constitutive Notch1 signaling.
As one might suspect, mutations in other genes that
participate in the Notch pathway can also cause activation
of the Notch pathway and are associated with tumorigenesis.
By speciﬁcally looking at T-ALL cell lines and patient samples
with constitutive expression of NICD but lacked C-terminal
PEST domain truncating mutations in NOTCH1, a study
identiﬁed either missense mutations or homozygous dele-
tions of the gene FBXW7 (FBW7), which codes for a ubiquitin
ligase that is critical in the degradation of NICD and is
dependent on binding to the PEST domain of Notch1.67 The
identiﬁed mutations affect residues within the substrate-
binding domain of FBXW7, impairing FBXW7–NICD interac-
tions and hence NICD ubiquitination. Due to the resulting
stabilizing effects on NICD, these FBXW7 mutations also
render the tumor cells resistant to gamma secretase inhib-
itors (GSI), a class of drug that usually decreases the level of
NICD by blocking the activation of Notch to NICD.67 NOTCH1
PEST domain mutations and FBXW7 mutations appeared to
be mutually exclusive in this study and another study,74 but
they were found to rarely coexist in a subsequent study,73
suggesting that FBXW7 mutations represent an alternative
pathway of Notch deregulation and pathogenesis for T-ALL.
Besides playing an important role in the pathogenesis of T-
ALL, recurrent NOTCH1mutations have also been identiﬁed in
chronic lymphocytic leukemia/small lymphocytic lymphoma
(CLL/SLL) in several studies,65,75,76 including a recent study
that detected a recurrent frameshift mutation (P2514fs) in a
subset of the 91 CLL patients during whole-exome and
-genome sequencing of matched leukemic cells and normal
tissue.77 The mutation rate was signiﬁcantly higher than the
background rate, suggesting NOTCH1 as a driver mutation in
CLL. This particular frameshift mutation is thought to result
in a premature stop codon resulting in a protein with a
truncated C-terminal PEST domain, leading to impaired
degradation and accumulation of the active isoform ofNotch1—NICD.65,76,77 The result is an activation of the Notch
pathway, as demonstrated by gene expression analysis of
differentially expressed genes in NOTCH1-mutated and
unmutated CLL cases.76 NOTCH1 mutation was also associ-
ated with unmutated immunoglobulin heavy chain (IGHV),
the presence of trisomy 12, higher rate of transformation into
DLBCL, more advanced clinical stage, and shorter overall
survival.65,76,77 Additionally, mutations in FBXW7 were also
detected in some cases of CLL,77 further implicating the
Notch1 pathway in the pathogenesis of this common mature
B-cell malignancy.
Just as in the other examples mentioned above, NOTCH1
mutations resulting in an accumulation of activated Notch1
protein (NICD1) can be detected by IHC. IHC is especially
helping in screening for activating NOTCH1 mutations, as
genetic screening is difﬁcult, considering the large size of the
NOTCH1 gene and the variety of genetic alterations described
so far.68 Kluk et al. made use of a rabbit monoclonal antibody
speciﬁc for a neo-epitope at the amino terminus of NICD1,
resulting from the proteolysis of Notch1 by a gamma secre-
tase. The study showed either diffuse nuclear or no positivity
by IHC in FFPE tissue sections of T-ALL cases, thought to
correspond to the NOTCH-mutated and unmutated cases,
respectively. Staining for CLL/SLL cases was more variable,
with close to 90% of cases showing positivity in at least 10% of
tumor cells, but 33% of cases showing positivity in 450% of
tumor cells, and 15% of cases being positive in480% of tumor
cells. Deep sequencing on frozen tissue identiﬁed NOTCH1
activating mutation in 17% of the cases, most commonly the
frameshift mutation in codon 2514 mentioned above.
Although there was a correlation between the percentage of
mutated reads by sequencing, and the percentage of positive
tumor nuclei by NICD1 IHC among the NOTCH1-mutated
cases (p o 0.0005), some CLL/SLL cases with wild-type
NOTCH1 alleles showed signiﬁcant positivity for NICD1 stain-
ing. It was thought that among these wild-type cases, micro-
environmental factors, such as the presence of Notch ligands,
mediated Notch1 activation. This hypothesis was supported
by the observation that NICD1 IHC staining was much weaker
in tumor cells found in perinodal soft tissue when compared
to tumor cells within the adjacent nodal tissue.68 Fig. 4 shows
two cases of CLL/SLL, one with a high fraction of tumor cells
being positive for NICD1 IHC staining and the other with
almost no tumor cells being positive. The NOTCH1 p2514fs
mutation status for both cases was conﬁrmed by pyrose-
quencing. In the study by Kluk et al.,68 NICD1 staining was
also positive in some cases of various types of peripheral T-
cell lymphomas, such as angioimmunoblastic lymphoma, but
the role of NOTCH1 activating mutations in this lymphoma
group is still unclear.
Overall, the presence of activating NOTCH1 mutations, as
well as other mutations resulting in the activation of the
Notch pathway, can be detected by IHC for NICD1, the
activated form of the Notch1 protein. IHC is particularly
useful in this situation, as genetic mutation analysis is
difﬁcult due to the large size of the NOTCH1 gene and the
variety of known genetic alterations in the NOTCH1 gene as
well as related genes such as FBXW7. For T-ALL cases, the
correlation between NICD1 positivity by IHC and activating
NOTCH1 mutations appears to be more straightforward,
Fig. 4 – NICD1 IHC in two chronic lymphocytic leukemia/small lymphocytic lymphomas (CLL/SLL). (A) CLL/SLL case with a high
amount of tumor cell NICD1 staining, which was conﬁrmed to harbor the NOTCH1 P2514fs frameshift mutation by
pyrosequencing. (B) CLL/SLL case with a very low amount of tumor cell NICD1 staining, which was conﬁrmed not to harbor the
NOTCH1 P2514fs frameshift mutation by pyrosequencing.
S E M I N A R S I N D I A G N O S T I C P A T H O L O G Y 3 2 ( 2 0 1 5 ) 3 8 1 – 3 9 1 387while for CLL, it appears to be more complicated, with an
apparently high negative predictive value but a less robust
positive predictive value. Regardless of this, the use of
NICD1 IHC on T-ALL and CLL patients can be helpful in
selecting patients for drug trials involving Notch pathway
inhibitors,71 as well as identifying the subset of CLL patients
with more rapid disease progression and poor prognosis,
who may require more frequent monitoring and aggressive
treatments.
PD-1 ligands
Programmed death-1 (PD-1) receptors are inducibly expressed
on activated T cells, and function to limit T-cell-mediated
immune responses. Normal antigen-presenting cells, dendritic
cells, and macrophages can express PD-1 ligands, which upon
binding to PD-1 receptors, leads to the attenuation of T-cell
receptor (TCR) signaling, which is essential in maintaining
immune tolerance and balanced responses to eliminate patho-
gens and tumor cells.78 PD-1 ligand 1 (PD-L1) is constitutively
expressed in a subset of cells of the hematopoietic lineage and
can be upregulated in solid tumors and certain hematologic
malignancies,79,80 while PD-1 ligand 2 (PD-L2) is usually indu-
cibly expressed on dendritic cells, macrophages, and mast
cells.79 PD-L1 can also competitively bind to CD80 (B7-1), the
ligand for CD28, a constitutively expressed receptor on T cells
that provide co-stimulatory signal for T-cell activation and
cytokine production.79 The result is a temporary and reversible
suppression of T-cell activation and proliferation.81 Further-
more, PD-L1 plays an essential role in the induction and
maintenance of induced regulatory T (iT reg) cell functioning,
including the suppression of effector T cells, inhibition of
immune-mediated tissue damage, and peripheral immune
tolerance.82 Due to its role in suppressing T-cell activation
and effector T cells, one can see why the PD-1 pathway can be
utilized by tumors to reduce or evade the host antitumor
immune responses.The signiﬁcance of the PD-1/PD-ligand signaling axis in
inhibiting antitumor immune responses has become appa-
rent with recent clinical trials. In a multicenter phase 1 drug
trial with an anti-PD-L1 antibody, which blocks the interac-
tion of PD-L1 with PD-1 on different types of advanced
cancers, partial or complete response was seen in a subset
of melanomas, renal cell carcinomas, non-small-cell lung
cancer, and ovarian cancers with sustained tumor regression
and disease stabilization at least 1 year after treatment.80
Another phase 1 trial published at the same time investigated
instead the use of anti-PD-1 antibody, which blocks the
interaction of PD-1 with its ligands, PD-L1 and PD-L2, in
treating various advanced malignancies.83 Partial or complete
response was again seen in a subset of melanomas, renal cell
carcinomas, and non-small-cell lung cancer, with durable
treatment response with at least 1 year of follow-up. Just as
in the anti-PD-L1 antibody trial, most treatment-related
adverse events were low grade, with some potential
immune-related adverse events. These data suggest that
immunotherapy targeting PD-1 and PD-L1 will be increasingly
integrated into the treatment of selected solid tumors.
Analyses of lymphoma cell lines and primary tissues have
revealed a genetic basis for PD-ligand expression. Using laser-
capture microdissection to purify Reed–Sternberg cells seen
in classical Hodgkin lymphomas (CHL), and high-resolution
array comparative genomic hybridization (aCGH) analysis,
Steidl et al.84 identiﬁed various recurrent chromosomal
abnormalities associated with CHL, including gains of chro-
mosome 9p, with 9p24.1–24.3 being one of the regions with
the most frequent chromosomal gains. Ampliﬁcation of the
9p24.1 locus in CHL was further characterized by Green
et al.81 using high-density single nucleotide polymorphism
(HD SNP) arrays with paired transcriptional proﬁles of CHL
cell lines, identifying CD274 (encoding PD-L1), PDCD1LG2
(encoding PD-L2), and Janus kinase 2 (JAK2), all located in
close proximity to each other at 9p24.1, as the target genes
of ampliﬁcation. Chromosome 9p24.1 ampliﬁcation was
F
s
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micro-dissected Reed–Sternberg cells in primary CHL.81
As predicted, increasing copy number of CD274 and
PDCD1LG2 encoded at 9p24.1 correlated with increased PD-
ligand expression. However, Green et al. also showed that
JAK2 copy gain also contributed to this effect. The CD274
promoter, and to a lesser extent the PDCD1LG2 promoter,
contains an interferon (IFN)-stimulated regulatory element/
IFN-regulatory factor 1 (ISRE/IRF1) module that is responsive
to JAK/STAT signaling. Ampliﬁcation of the JAK2 locus on
9p24.1 results in an increase in JAK2 transcript, phosphory-
lated (active) JAK2 and STAT1, and an induction of PD-L1 in
CHL cell lines in a manner sensitive to JAK2 inhibition.81 Thus
9p24.1 copy gain results in PD-ligand overexpression by
multiple, reinforcing mechanisms.
Perhaps not surprisingly, 9p24.1 copy gain is not restricted
to CHL. Primary mediastinal large B-cell lymphoma (PMBL) is
an entity with shared clinical and molecular genetic features
with CHL.85,86 Consistent with this, a subset of PMBL also has
9p24.1 copy gain and PMBL cell lines express the PD-ligands.81
A subset also overexpresses PD-L1 or PD-L2 due to chromo-
somal translocations involving CD274 or PDCD1LG2, respec-
tively. Twa et al.87 used a break-apart FISH assay to show that
20% of 125 cases of PMBL have chromosomal translocations, a
frequency much higher than other B-cell lymphomas. Using
qRT-PCR, PD-L1 and PD-L2 transcripts were shown to be
signiﬁcantly higher in translocation-positive cases compared
to cases with neutral copy numbers at 9p24.1.87
Finally, within classical Hodgkin lymphomas, chromosome
9p24.1 copy gain was speciﬁcally restricted to the EBV-negative,
nodular sclerosis subtype (NSHL). In EBV-positive tumors, an
alternative mechanism for PD-L1 expression was described.
Using EBV-transformed lymphoblastoid cell lines (LBLs), Green
et al.88 showed that the EBV-encoded latent membrane protein
(LMP-1) promotes constitutive activation of AP-1, an enhancer
element in CD274 (which encodes PD-L1), as well as JAK-STAT
signaling, which induces PD-L1 expression.
Due to the variety of mechanism that can drive PD-1 ligand
overexpression in lymphoid neoplasms (gene copy numberig. 5 – PD-L2 IHC in two primary mediastinal (thymic) large B-cell
taining for PD-L2. This case also demonstrated PDCD1LG2 copy n
taining for PD-L2. This case lacked PDCD1LG2 copy gain by qPCRgain, chromosomal translocation, JAK/STAT signaling, and
EBV-driven induction), the use of IHC would be expected to
have an advantage over targeted genetic testing. Chen et al.89
validated IHC for PD-L1 to conﬁrm protein expression in
Reed–Sternberg cells of CHL and malignant B-cells of PMBL.
That study also showed that PD-L1 expression was fairly
common among EBV-positive malignancies including EBV-
positive DLBCL (DLBCL of the elderly and immunodeﬁciency-
related DLBCL), EBV-positive post-transplant lymphoprolifer-
ative disorders (PTLD), plasmablastic lymphoma, extranodal
NK/T-cell lymphoma, and nasopharyngeal carcinoma.88,89 In
addition, PD-L1 was identiﬁed in a subset of EBV-negative
PTLD, HHV8-associated primary effusion lymphoma, and T-
cell/histiocyte-rich large B-cell lymphoma.89 On the other
hand, positivity for PD-L1 was uncommon among nodular
lymphocyte-predominant Hodgkin lymphoma (NLPHL);
DLBCL, not otherwise speciﬁed (NOS); Burkitt lymphoma;
and HHV8-associated Kaposi sarcoma.
An unanticipated result of these studies was the detection of
robust PD-L1 expression by non-neoplastic cells, primarily
macrophages, within the tumor microenvironment of many
PD-L1-positive malignancies.89 Indeed, for tumors such as CHL,
in which non-neoplastic inﬂammatory cells far exceed the
malignant Reed–Sternberg cells, the majority of PD-L1 protein
in the cellular microenvironment is attributable to tumor-
associated macrophages (TAMs) as demonstrated by double
staining for CD68 and PD-L1.89 The mechanism of PD-L1
induction in TAMs remains unclear, but cytokine-mediated
JAK/STAT signaling likely contributes. Moreover, it is not clear
whether PD-L1 positivity in TAMs is associated with tumor
aggressiveness and prognosis. However, several studies have
described an association between increased TAMs in CHL and
shorter disease-free and overall survival rates.90,91
More recently, Shi et al.92 validated IHC for PD-L2 and
demonstrated that over 70% of PMBL cases, and only 3% of
DLBCL cases, showed membranous positivity by IHC in at
least 20% of tumor cells. The majority of PMBL cases showed
3þ (strong) staining in the majority of the tumor cells, while
the one case of DLBCL that was positive showed staining inlymphomas (PMBL). (A) PMBL showing positive membrane
umber gain by qPCR. (B) PMBL showing no membrane
.
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PCR, 75% of PMBLs with frozen and parafﬁn-embedded
tissues available showed ampliﬁcation of the PDCD1LG2 gene,
which were all positive for PD-L2 by IHC. High copy number
gain of PDCD1LG2 was associated with intense membranous
positivity for PD-L2 by IHC. On the contrary, none of the
DLBCLs showed gain of copy number of PDCD1LG2.92 Fig. 5
shows examples of PMBL with or without PD-L2 expression by
IHC that are in accordance with genetic analyses.
Immunohistochemical testing for PD-ligand expression
may prove important for the selection of patients who are
likely to respond to targeted immunotherapy. In the phase I
trial of a PD-1 inhibitor in patients with solid tumors, a subset
of patients (36%) who had PD-L1-positive tumors had objec-
tive response to the anti-PD-1 drug, while none of the
patients who had PD-L1-negative tumors had objective
response.83 A trial of an anti-PD-1 antibody (Nivolumab) in
23 patients with relapsed/refractory Hodgkin lymphomas
suggests a high response rate (17% with complete response
and 70% with partial response) among patients with Hodgkin
lymphoma positive for PD-ligand expression.93
As a summary, the use of IHC for PD-L1 and PD-L2 can be
helpful for diagnostic purposes, such as in the case of differ-
entiating PMBL from DLBCL, and may yet prove predictive of
tumor responses to anti-PD-1 or anti-PD-L1 therapies. The
use of IHC has many advantages in the case of PD-1 ligands,
as the variety of mechanisms causing PD-L1 and PD-L2
overexpression (chromosomal copy gain, translocation, cyto-
kine-mediated, and EBV-driven induction) creates difﬁculties
in detection when relying upon genetics studies alone. IHC
also captures PD-ligand expression by non-neoplastic cells
within the tumor microenvironment, which may contribute
to the overall immune evasion strategy of a tumor.Conclusions
The examples above show that IHC can be an economical and
reliable method of detecting underlying genetic aberrations
in lymphoid neoplasms. It can be performed routinely in
many pathology laboratories and requires less instrumenta-
tion and personnel expertise necessary for genetic analyses
such as karyotyping, FISH, and PCR mutation studies. In the
cases of MYC, BCL2, Notch1, and PD-1 ligands, not only can
IHC capture dysregulated protein expression due to known
and speciﬁc genetic lesions, it can also serve as a common
ﬁnal read-out for other known and unknown genetic lesions,
epigenetic modiﬁcations, or microenvironmental regulation
that result in dysregulated protein expression. Thus, IHC
captures information that has diagnostic, prognostic, and
therapeutic implications, which may not be detected by
genetic analyses alone. Moreover, the use of IHC also allows
the concurrent evaluation of staining pattern, tissue archi-
tecture, and cellular morphology. However, from the exam-
ples above, it is also apparent that the selection of
appropriate and speciﬁc antibodies, a rigorous validation
process, use of relevant controls, and standards for compar-
isons are all crucial for performing IHC. It is also important to
understand that certain genetic mutations, as in the case of
BCL2, can result in false negativity due to the loss of arecognizable epitope by the antibody. Genetic analysis also
has the advantage of a digital read-out, which may be
important from the perspectives of treatment decision-
making and disease monitoring. In the future, pathologists
will be required to integrate the complementary data from
multiple diagnostic modalities including IHC and genetics to
classify lymphoid malignancies with greater precision.Acknowledgment
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